CSIMarket
 
Glucotrack Inc   (NASDAQ: GCTK)
Other Ticker:  
 
 
Price: $0.7090 $-0.10 -12.469%
Day's High: $0.83 Week Perf: 898.59 %
Day's Low: $ 0.49 30 Day Perf: 141.73 %
Volume (M): 5,788 52 Wk High: $ 3.13
Volume (M$): $ 4,104 52 Wk Avg: $1.20
Open: $0.82 52 Wk Low: $0.05



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Glucotrack Inc
Glucotrack Inc is a medical technology company that specializes in the development and manufacturing of non-invasive glucose monitoring devices. The company's flagship product, also called Glucotrack, is designed to help people with diabetes manage their blood sugar levels more easily and conveniently. Unlike traditional glucose monitoring devices that require blood samples, Glucotrack uses a combination of ultrasonic, electromagnetic, and thermal technologies to measure glucose levels in the saliva or outer earlobe. This non-invasive approach eliminates the need for painful finger pricking and provides accurate and real-time glucose readings. The company aims to improve the lives of individuals with diabetes by offering a non-invasive and user-friendly alternative to glucose monitoring.


   Company Address: 301 Route 17 North Rutherford 7070 NJ
   Company Phone Number: 842-7715   Stock Exchange / Ticker: NASDAQ GCTK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DRIO   -1.75%    
DXCM        1.32% 
MDT        0.31% 
MOVE        1.71% 
NDRA        0.2% 
UBI        0.2% 
• View Complete Report
   



Management Changes

Glucotracks Strategic Reinforcement: Industry Veteran Peter C. Wulff Appointed CFO Amidst Financial Challenges

Published Wed, Jan 29 2025 2:01 PM UTC

In a significant development for Glucotrack, the company has bolstered its executive leadership with the appointment of industry veteran Peter C. Wulff as the new Chief Financial Officer. This strategic move comes at a crucial time as Glucotrack seeks to enhance its financial strategy and accelerate the commercialization of its innovative continuous blood glucose monitor, sp...

Glucotrack Inc

Medical Equipment & Supplies Company Skyrockets with $2.951 Million Operating Income in Recent Fiscal Period



Investors of medical technology company Glucotrack Inc (GCTK) have displayed an optimistic sentiment during the earnings season for the January to March 31, 2024 period. Although shareholders initially did not anticipate any major changes, the company's operating income of $2.951 million during this timeframe has caught their attention. Recent operational decisions have overshadowed the previous financial year's results, highlighting the company's progress in research and development. With a commendable uptick in net earnings and operating income, we delve into Glucotrack Inc's current performance and future prospects.
Positive Quarter Results
Glucotrack Inc, a leading provider of medical equipment and supplies, has exhibited strong performance in the first quarter of 2024. The company's net earnings have surged from $1.286 million in Q1 2023 to an impressive $2.927 million in the same period this year. This signifies a substantial growth of 127.6% in net earnings, showcasing the company's successful efforts to enhance profitability.

Glucotrack Inc

Investors Beware: Declining Profitability Raises Concerns for Glucotrack Inc. in the Medical Equipment & Supplies Industry

As a Wall Street journalist following the Medical Equipment & Supplies industry, it is important to take a closer look at the recent financial results of Glucotrack Inc. The fourth quarter of 2023 has brought mixed news for the corporation, with some concerning trends emerging.
While Glucotrack Inc. reported an operating income of $2.417 million for the fourth quarter of 2023, a closer look at the numbers reveals a significant drop in profitability. Net profits have declined by -55.31%, falling from $5.397 million in the same quarter of 2022 to $2.412 million in 2023. This decline has also impacted the company's operating margin, which now stands at 0%.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com